Primary tumor surgery
ProcedureLarge bowel resection.
Other names: Bowel resection
NCT Number: NCT04735198
The investigators want to study the effectiveness of prophylactic cholecystectomy in patients with midgut neuroendocrine tumor (jejunum, ileum or proximal colon) who require primary tumor surgery. When patients are diagnosed and are tributary to surgical treatment, the tumor might compromise vascularization, and patients need an extensive bowel resection. The patients might also receive medical treatment with somatostatin analogs. The combination of extensive bowel resection and medical treatment might increase gallbladder stones, but patients might not develop biliary stone disease, as in the general population, where 20% of the population have gallbladder stones but only a 10 to 15 % of the population will develop symptoms.
The idea comes from the lack of literature about the incidence of biliary Stone disease in patients with midgut NET tumors.
It's a multicentric, open-label and randomized clinical trial to evaluate the incidence of biliary stone disease in patients with midgut NET who require primary tumor surgery combined or not to cholecystectomy.
Our hypothesis suggests that patients with midgut neuroendocrine tumor who require primary tumor resection without the combination of prophylactic cholecystectomy do not have an increased incidence of biliary stone disease two years after the surgery, regardless of treatment with SSA.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Hospital Universitari Trias i Pujol, Badalona, Barcelona, Spain
Title: Effectiveness of prophylactic cholecystectomy in patients with midgut neuroendocrine tumor (jejunum, ileum or proximal colon) who require primary tumor surgery. Randomized, proof of concept clinical trial.
Background: The prevalence of midgut NET has increased due to advances in diagnostic tests and its indolent course. When patients are diagnosed, they might be tributary to surgical treatment requiring an extensive bowel resection, and medical treatment with somatostatin analogs. Both treatments are related with gallbladder stone formation. The ENETS and NANETs recommend prophylactic cholecystectomy in patients with midgut NET who require primary tumor surgery, However, there is a lack of scientific evidence reinforcing this recommendation.
Objectives: The main objective is to evaluate the cumulated incidence rate of biliary stone disease in patients with midgut NET who require primary tumor resection, two years after the surgery.
Design: It's a multicentric, open-label and randomized clinical trial. Patients will be recruited from the General Surgery Services of the six Hospitals participating in the study. Patients must fullfill inclusion and exclusion criteria.
It is expected to recruit a maximum of one hundred patients in two years (50 per group). Patients will be randomly assigned into the Experimental group (primary tumor resections) or Control group (primary tumor resections combined with cholecystectomy). The investigators will follow up patients until week 104 after surgery (8 visits).
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Large bowel resection.
Other names: Bowel resection
Large bowel resection combined and cholecystectomy.
Other names: prophylactic cholecystectomy.
Time frame: Two years after the surgery
Incidence of biliary stone disease in patients with midgut NET who requiere primary tumor surgery
Time frame: One month after the surgery
Postoperative complications according Clavien-Dindo classification
Time frame: One month after the surgery
Specific complications
Time frame: Two years after the surgery
choledochal lithiasis or cholelithiasis
Time frame: Two years after the surgery
choledochal lithiasis or cholelithiasis according medical treatment
Time frame: Two years after the surgery
Gastrointestinal Quality of Life Index (GIQLY);Minimum value of 0 (the worst health state) and a maximum of 100 (best health state)
Time frame: Two years after the surgery
Health related Quality of life 15 D (HRQoL 15D);There are 15 areas with a minimum value of 0 (the worst health state) and a maximum of 100 (best health state) 15D
Contact information is provided by the study sponsor or research team.
Hospital Universitari de Bellvitge
Other
Effectiveness of Prophylactic Cholecystectomy in Patients With Midgut Neuroendocrine Tumor (Jejunum, Ileum or Proximal Colon) Who Require Primary Tumor Surgery. Randomized, Proof of Concept Clinical Trial.
Acronym: TNE-IDC-COLE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03244163
Biliary Stones, Biliary Tract Diseases
Hong Kong, NT
View Trial DetailsNCT05210322
Adenocarcinoma, Bile Duct Diseases
Baltimore, Maryland, United States
View Trial DetailsNCT03421340
Bile Duct Diseases, Biliary Stones
Stanford, California, United States
View Trial DetailsNCT06340594
Bile Duct Diseases, Biliary Stones
Asyut, Asyut Governorate, Egypt
View Trial Details